Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus
| Status: | Recruiting |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 10/24/2015 |
| Start Date: | March 1995 |
| Contact: | Ann C. M. Smith |
| Email: | acmsmith@nhgri.nih.gov |
| Phone: | (301) 435-5475 |
The aim of the project is to positionally clone susceptibility genes for NIDDM. Patients
will be ascertained in Finland from previous health surveys and hospital discharge records.
Approximately 400 affected sib pairs will be collected. Families will be chosen who have, at
most, one parent with NIDDM no history of IDDM. A clinical examination will be undertaken on
family members and blood drawn for DNA isolation. Covariates such as body weight, blood
pressure, lipid levels and urinary albumin will also be measured. The unaffected spouse and
children of a subset of probands will be invited to undergo a frequently-sampled intravenous
glucose tolerance test (FSIGT) to measure parameters of pancreatic function and peripheral
insulin resistance (IR). A number of unrelated elderly non-diabetic subjects will also be
identified to conduct a population-based association analysis.
The FSIGT analysis will be performed in Los Angeles. The DNA will be shipped to Bethesda
where a total genomic scan will be performed using semi-automated fluorescence-based
genotyping technology. Data from Bethesda, Los Angeles and Finland will be sent to Ann Arbor
where parametric and non-parametric methods will be used to analyse both discrete traits
such as NIDDM and intermediate traits like IR.
will be ascertained in Finland from previous health surveys and hospital discharge records.
Approximately 400 affected sib pairs will be collected. Families will be chosen who have, at
most, one parent with NIDDM no history of IDDM. A clinical examination will be undertaken on
family members and blood drawn for DNA isolation. Covariates such as body weight, blood
pressure, lipid levels and urinary albumin will also be measured. The unaffected spouse and
children of a subset of probands will be invited to undergo a frequently-sampled intravenous
glucose tolerance test (FSIGT) to measure parameters of pancreatic function and peripheral
insulin resistance (IR). A number of unrelated elderly non-diabetic subjects will also be
identified to conduct a population-based association analysis.
The FSIGT analysis will be performed in Los Angeles. The DNA will be shipped to Bethesda
where a total genomic scan will be performed using semi-automated fluorescence-based
genotyping technology. Data from Bethesda, Los Angeles and Finland will be sent to Ann Arbor
where parametric and non-parametric methods will be used to analyse both discrete traits
such as NIDDM and intermediate traits like IR.
The Finland-United States investigation of NIDDM (FUSION) study is a long-term effort to
identify susceptibility genes for Type 2 diabetes (T2D) and associated quantitative traits.
This
involves the phenotyping and DNA analysis of thousands of individuals living in Finland,
utilizing a study design that was originally based on affected sib pairs. The majority of
these samples have already been subjected to a genome scan using microsatellite markers and
the original FUSION samples. Additionally, thousands of other northern European cases and
controls have been subjected to genome-wide association (GWA) analysis and/or fine mapping
as part of the FUSION study. More recently, the opportunity provided by the lowered
sequencing costs have allowed targeted and/or whole genome sequencing of many of these
individuals.
identify susceptibility genes for Type 2 diabetes (T2D) and associated quantitative traits.
This
involves the phenotyping and DNA analysis of thousands of individuals living in Finland,
utilizing a study design that was originally based on affected sib pairs. The majority of
these samples have already been subjected to a genome scan using microsatellite markers and
the original FUSION samples. Additionally, thousands of other northern European cases and
controls have been subjected to genome-wide association (GWA) analysis and/or fine mapping
as part of the FUSION study. More recently, the opportunity provided by the lowered
sequencing costs have allowed targeted and/or whole genome sequencing of many of these
individuals.
- No eligibility criteria listed.
We found this trial at
1
site
Click here to add this to my saved trials
